Expert Interview
An updated look at Nektar Therapeutics’ Phase 2b REZOLVE-AA study results evaluating rezpegaldesleukin in patients with severe-to-very-severe alopecia areata
Ticker(s): NKTRInstitution: Harvard Medical School
Associate Professor of Dermatology at Harvard Medical School and Vice Chair of Clinical Trials and Innovation at Brigham and Women’s Hospital
Currently manages over 150 patients with alopecia areata.
Reseaarch focus on alopecia areata, complex medical dermatology, diagnostic testing, and health disparities.
What is your overall interpretation of the Phase 2b REZOLVE-AA results for rezpegaldesleukin in severe-to-very-severe alopecia areata, and what do you view as the key clinical takeaways?
Added By: sara_adminHow meaningful were the observed hair regrowth outcomes (e.g., SALT response thresholds) in the context of severe AA, and how do these results compare with what you see with current standards of care (including JAK inhibitors)?
Added By: sara_adminWhat safety/tolerability considerations matter most for long-term AA therapy, and based on the Phase 2b profile, what stands out to you as either reassuring or concerning?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
